Methylphenidate Xiromed

Methylphenidate, the active ingredient in Methylphenidate Xiromed, is a central nervous system stimulant presented as an oral formulation for oral use. It is used to treat attention deficit hyperactivity disorder and narcolepsy in children, adolescents and adults. GNH USA supplies Methylphenidate Xiromed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate Xiromed acts on central nervous system pathways to improve attention and reduce excessive daytime sleepiness.

- Attention deficit hyperactivity disorder (ADHD): improves focus, reduces hyperactivity and impulsivity. - Narcolepsy: decreases daytime sleepiness and cataplexy episodes. - Attention deficit disorder (ADD): provides similar symptom control as in ADHD.

Methylphenidate Xiromed may cause a range of adverse reactions.

Common Side Effects: - Insomnia - Decreased appetite - Headache - Stomach pain

Serious or Rare Side Effects: - Cardiovascular events such as hypertension or tachycardia - Psychotic symptoms including hallucinations or delusions - Severe allergic reaction (anaphylaxis).

Before prescribing Methylphenidate Xiromed, consider the following safety measures.

- Assess cardiovascular status: evaluate blood pressure and heart rate prior to initiation. - Monitor growth in children: regularly track weight and height. - Avoid use in patients with known hypersensitivity to methylphenidate. - Use caution in individuals with a history of psychiatric disorders. - Pregnancy Category C: discuss potential risks with the prescriber. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Methylphenidate Xiromed can interact with several other medicines.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular effects. - Antihypertensive agents: may reduce their efficacy. - Severe liver impairment: may raise plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors: may elevate methylphenidate levels. - Diuretics: may enhance blood pressure fluctuations.